$HEPA Cashflow Statement | Understand Stock

$HEPA

$0.09 +$0.02 (33.33%) Close

$HEPA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation
Asset impairment loss
Depreciation
Amortization of debt discount
Inducement expense
Write-off related party note receivable
Change in fair value of contingent consideration
Impairment of goodwill
Change in deferred tax liability
Impairment of in-process research and development
Changes in operating assets and liabilities:
Accounts payable and accrued expenses
Right of use asset
Operating lease liability
Prepaid expenses and other assets

Net cash used in operating activities
Cash flows from investing activities:
Purchase of property and equipment
Proceeds from disposal of property and equipment
Investment in license agreement
Investment in related party receivable
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from the issuance of common stock and warrants, net of issuance costs
Proceeds from the issuance of common stock and warrants, net
Proceeds from debt financing
Proceeds from the issuance of Series F and Series G Redeemable Preferred Stock, net of issuance costs
Repayment of debt financing
Contingent consideration milestone payment
Equity issuance costs
Proceeds from equity and debt issuance under SPA, net of discount
Payments on notes payable
Net cash (used in) provided by financing activities

Effect of exchange rates on cash
Net increase (decrease) in cash
Cash at beginning of period
Cash at end of period
Supplementary disclosure of cash flow information:
Cash paid for interest
Supplementary disclosure of non-cash financing activities:
Conversion of Series C convertible preferred stock
Issuance of common stock in conjunction with milestone payment
Fair value of warrants issued to placement agent
Adoption of new accounting standard
Issuance of Note Payable for payment of prepaid expense
Inducement expense for issuance of Series B-1 and B-2 warrants
Stock-based liability awards reversed to additional paid-in capital
Operating lease asset additions
Cashless Exercise of 2025 Series B Warrants
Issuance of common stock in connection with license agreement

Comments